Does the media refer more to CTMX or SRPT?

In the previous week, Sarepta Therapeutics had 17 more articles in the media than CytomX Therapeutics. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 2 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.18 beat Sarepta Therapeutics' score of 0.05 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to EDIT or SRPT?

In the previous week, Sarepta Therapeutics had 17 more articles in the media than Editas Medicine. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.94 beat Sarepta Therapeutics' score of 0.05 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer IMVT or SRPT?

In the previous week, Sarepta Therapeutics had 6 more articles in the media than Immunovant. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 13 mentions for Immunovant. Immunovant's average media sentiment score of 0.46 beat Sarepta Therapeutics' score of 0.05 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor SRPT or RYTM?

In the previous week, Sarepta Therapeutics had 16 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Sarepta Therapeutics' score of 0.05 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRPT or MIRM?

In the previous week, Sarepta Therapeutics had 9 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 10 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.78 beat Sarepta Therapeutics' score of 0.05 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Mirum Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sarepta Therapeutics (SRPT) Competitors

$18.82 -0.13 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$18.73 -0.09 (-0.46%)

As of 06:49 PM Eastern

Compare

SRPT vs. CTMX, EDIT, IMVT, RYTM, and MIRM

Should you buy Sarepta Therapeutics stock or one of its competitors? MarketBeat compares Sarepta Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Sarepta Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

In the previous week, Sarepta Therapeutics had 17 more articles in the media than CytomX Therapeutics. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 2 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.18 beat Sarepta Therapeutics' score of 0.05 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 227.03%. Sarepta Therapeutics has a consensus target price of $25.09, indicating a potential upside of 33.32%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Sarepta Therapeutics	7 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08

CytomX Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	8.26	-$17.37M	-$0.41	N/A
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A

CytomX Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

Sarepta Therapeutics has a net margin of -2.94% compared to CytomX Therapeutics' net margin of -166.40%. Sarepta Therapeutics' return on equity of 7.56% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

Summary

CytomX Therapeutics beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Sarepta Therapeutics had 17 more articles in the media than Editas Medicine. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.94 beat Sarepta Therapeutics' score of 0.05 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Editas Medicine has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	7.64	-$160.06M	-$1.23	N/A
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A

Editas Medicine currently has a consensus price target of $5.40, suggesting a potential upside of 70.89%. Sarepta Therapeutics has a consensus price target of $25.09, suggesting a potential upside of 33.32%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Sarepta Therapeutics	7 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08

Editas Medicine has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sarepta Therapeutics has a net margin of -2.94% compared to Editas Medicine's net margin of -281.59%. Sarepta Therapeutics' return on equity of 7.56% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

Summary

Sarepta Therapeutics beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Immunovant has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

47.1% of Immunovant shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immunovant presently has a consensus target price of $39.70, indicating a potential upside of 2.58%. Sarepta Therapeutics has a consensus target price of $25.09, indicating a potential upside of 33.32%. Given Sarepta Therapeutics' higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Sarepta Therapeutics	7 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Sarepta Therapeutics had 6 more articles in the media than Immunovant. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 13 mentions for Immunovant. Immunovant's average media sentiment score of 0.46 beat Sarepta Therapeutics' score of 0.05 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Immunovant has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A

Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Summary

Sarepta Therapeutics beats Immunovant on 9 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Rhythm Pharmaceuticals?

Sarepta Therapeutics (NASDAQ:SRPT) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Sarepta Therapeutics had 16 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Sarepta Therapeutics' score of 0.05 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Sarepta Therapeutics. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A
Rhythm Pharmaceuticals	$189.76M	38.82	-$196.54M	-$3.13	N/A

Sarepta Therapeutics currently has a consensus price target of $25.09, suggesting a potential upside of 33.32%. Rhythm Pharmaceuticals has a consensus price target of $138.29, suggesting a potential upside of 28.65%. Given Sarepta Therapeutics' higher possible upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	7 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Sarepta Therapeutics has a net margin of -2.94% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Sarepta Therapeutics' return on equity of 7.56% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

86.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sarepta Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

Summary

Sarepta Therapeutics beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Mirum Pharmaceuticals?

Sarepta Therapeutics (NASDAQ:SRPT) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sarepta Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Sarepta Therapeutics presently has a consensus target price of $25.09, suggesting a potential upside of 33.32%. Mirum Pharmaceuticals has a consensus target price of $143.40, suggesting a potential upside of 20.46%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	7 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Sarepta Therapeutics had 9 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 10 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.78 beat Sarepta Therapeutics' score of 0.05 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A
Mirum Pharmaceuticals	$569.61M	12.74	-$23.36M	-$13.61	N/A

Sarepta Therapeutics has a net margin of -2.94% compared to Mirum Pharmaceuticals' net margin of -140.24%. Sarepta Therapeutics' return on equity of 7.56% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRPT vs. The Competition

Export

Metric	Sarepta Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.99B	$3.67B	$6.83B	$12.42B
Dividend Yield	N/A	2.19%	2.68%	8.01%
P/E Ratio	-19.60	21.03	27.15	24.29
Price / Sales	0.90	217.66	524.33	95.60
Price / Cash	N/A	61.98	29.22	49.39
Price / Book	1.73	8.49	10.75	6.29
Net Income	-$713.41M	$23.83M	$3.58B	$330.86M
7 Day Performance	-1.88%	-3.18%	-2.10%	-2.41%
1 Month Performance	22.93%	6.31%	3.32%	-0.64%
1 Year Performance	3.58%	52.74%	28.17%	20.09%

Sarepta Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRPT Sarepta Therapeutics	2.9227 of 5 stars	$18.82 -0.7%	$25.09 +33.3%	+4.3%	$1.99B	$2.20B	N/A	1,372
CTMX CytomX Therapeutics	2.5658 of 5 stars	$3.81 -0.3%	$12.10 +217.6%	+55.4%	$650.11M	$76.20M	N/A	170	Positive News
EDIT Editas Medicine	2.5539 of 5 stars	$3.65 flat	$5.40 +47.9%	+13.2%	$357.36M	$40.52M	N/A	230
IMVT Immunovant	2.1401 of 5 stars	$38.60 -0.5%	$39.70 +2.8%	+119.0%	$7.96B	N/A	N/A	120	News Coverage Insider Trade
RYTM Rhythm Pharmaceuticals	3.2662 of 5 stars	$111.68 -2.2%	$133.13 +19.2%	+25.0%	$7.82B	$189.76M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRPT) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, IMVT, RYTM, and MIRM

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Summary

How does Sarepta Therapeutics compare to Immunovant?

Summary

How does Sarepta Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Sarepta Therapeutics compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, IMVT, RYTM, and MIRM

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Does the media refer more to CTMX or SRPT?

Do institutionals & insiders believe in CTMX or SRPT?

Do analysts rate CTMX or SRPT?

Which has preferable earnings and valuation, CTMX or SRPT?

Which has more volatility & risk, CTMX or SRPT?

Is CTMX or SRPT more profitable?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Does the media refer more to EDIT or SRPT?

Which has higher earnings & valuation, EDIT or SRPT?

Do analysts rate EDIT or SRPT?

Which has more risk & volatility, EDIT or SRPT?

Do insiders and institutionals have more ownership in EDIT or SRPT?

Is EDIT or SRPT more profitable?

Summary

How does Sarepta Therapeutics compare to Immunovant?

Is IMVT or SRPT more profitable?

Do institutionals and insiders believe in IMVT or SRPT?

Do analysts prefer IMVT or SRPT?

Does the media prefer IMVT or SRPT?

Which has better earnings and valuation, IMVT or SRPT?

Which has more risk & volatility, IMVT or SRPT?

Summary

How does Sarepta Therapeutics compare to Rhythm Pharmaceuticals?

Does the media favor SRPT or RYTM?

Which has stronger valuation and earnings, SRPT or RYTM?

Do analysts rate SRPT or RYTM?

Is SRPT or RYTM more profitable?

Do insiders & institutionals believe in SRPT or RYTM?

Which has more risk and volatility, SRPT or RYTM?

Summary

How does Sarepta Therapeutics compare to Mirum Pharmaceuticals?

Do institutionals and insiders believe in SRPT or MIRM?

Which has more risk & volatility, SRPT or MIRM?

Do analysts rate SRPT or MIRM?

Does the media favor SRPT or MIRM?

Which has better earnings & valuation, SRPT or MIRM?

Is SRPT or MIRM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools